Hunan Er-Kang Pharmaceutical Co., Ltd

300267

CNE100001781

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 18/06/2024 BST			5-day change	1st Jan Change
2.24 ^CNY	-1.75%		-3.03%	-30.22%

04-26	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hunan Er-Kang Pharmaceutical Co., Ltd(SZSE:300267) dropped from Shenzhen Stock Exchange Component A Share Index

January 01, 2018 at 05:00 am

Hunan Er-Kang Pharmaceutical Co., Ltd has been removed from Shenzhen Stock Exchange Component A Share Index .

Latest news about Hunan Er-Kang Pharmaceutical Co., Ltd

Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	22/10/23	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27/08/23	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	26/04/23	CI
ER-KANG Pharma Earmarks $140 Million for Lithium Carbonate Factory; Shares Gain 7%	17/11/22	MT
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes	15/11/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	27/04/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million.	27/10/21	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	27/10/21	CI
Hunan Er-Kang Pharmaceutical Co., Ltd(XSEC:300267) added to S&P Global BMI Index	20/09/21	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	26/08/21	CI
Xu Zhiqi completed the acquisition of 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd from Hunan Shuaijia Investment Co., Ltd.	20/07/21	CI
An unknown buyer agreed to acquire 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd for approximately CNY 200 million.	01/07/21	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021	28/04/21	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020	12/10/20	CI
Huang Shubiao, Xiao Qingguang, Wu Kaijian, and Huang Linggang completed the acquisition of 95% stake in Guangdong Yueerkang Pharmaceutical Co., Ltd. from Hunan Er-Kang Pharmaceutical Co., Ltd.	23/09/20	CI
Hunan Er-Kang Pharmaceutical Co., Ltd's Equity Buyback announced on March 20, 2020, has expired.	18/09/20	CI
Huang Shubiao, Xiao Qingguang, Wu Kaijian, and Huang Linggang agreed to acquire 95% stake in Guangdong Yueerkang Pharmaceutical Co., Ltd. from Hunan Er-Kang Pharmaceutical Co., Ltd for approximately CNY 100 million.	27/08/20	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020	27/08/20	CI
Hunan Er-Kang Pharmaceutical Co., Ltd signed an equity transfer agreement to acquire Wuzhiwei Er-Kang Biochemical Pharmaceutical Co., Ltd. from Nanyu Xingkang Pharmaceutical Co., Ltd. for CNY 58 million.	07/05/20	CI

Chart Hunan Er-Kang Pharmaceutical Co., Ltd

Duration

Period

Chart Hunan Er-Kang Pharmaceutical Co., Ltd

More charts

HUNAN ER-KANG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and sales of pharmaceutical excipients, finished drugs and bulk drugs. The Companyâs pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD	-30.22%	637M
ELI LILLY AND COMPANY	+52.93%	803B
NOVO NORDISK A/S	+41.25%	631B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.51%	243B
ROCHE HOLDING AG	+2.13%	228B
NOVARTIS AG	+10.32%	217B
AMGEN INC.	+6.24%	164B